Fluorinated tracers for imaging cancer with positron emission tomography
- 6 July 2004
- journal article
- review article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 31 (8) , 1182-1206
- https://doi.org/10.1007/s00259-004-1607-9
Abstract
2-[18F]fluoro-2-deoxy-d-glucose (FDG) is currently the only fluorinated tracer used in routine clinical positron emission tomography (PET). Fluorine-18 is considered the ideal radioisotope for PET imaging owing to the low positron energy (0.64 MeV), which not only limits the dose rate to the patient but also results in a relatively short range of emission in tissue, thereby providing high-resolution images. Further, the 110-min physical half-life allows for high-yield radiosynthesis, transport from the production site to the imaging site and imaging protocols that may span hours, which permits dynamic studies and assessment of potentially fairly slow metabolic processes. The synthesis of fluorinated tracers as an alternative to FDG was initially tested using nucleophilic fluorination of the molecule, as performed when radiolabelling with iodine-124 or bromide-76. However, in addition to being long, with multiple steps, this procedure is not recommended for bioactive molecules containing reactive groups such as amine or thiol groups. Radiochemical yields are also often low. More recently, radiosynthesis from prosthetic group precursors, which allows easier radiolabelling of biomolecules, has led to the development of numerous fluorinated tracers. Given the wide availability of 18F, such tracers may well develop into important routine tracers. This article is a review of the literature concerning fluorinated radiotracers recently developed and under investigation for possible PET imaging in cancer patients. Two groups can be distinguished. The first includes “generalist” tracers, i.e. tracers amenable to use in a wide variety of tumours and indications, very similar in this respect to FDG. These are tracers for non-specific cell metabolism, such as protein synthesis, amino acid transport, nucleic acid synthesis or membrane component synthesis. The second group consists of “specific” tracers for receptor expression (i.e. oestrogens or somatostatin), cell hypoxia or bone metabolism.Keywords
This publication has 99 references indexed in Scilit:
- 6α-[18F]Fluoroprogesterone: Synthesis via halofluorination-oxidation, receptor binding and tissue distributionNuclear Medicine and Biology, 1995
- Amino acids for the measurement of protein synthesis in vivo by PETInternational Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology, 1992
- A comparative PET study using different 11C-labelled amino acids in Walker 256 carcinosarcoma-bearing ratsInternational Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology, 1991
- [111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validationLife Sciences, 1991
- Comparison of the substrate specificities of human thymidine kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogsBiochemical and Biophysical Research Communications, 1991
- Characterization of the uptake of 16α-([18F]fluoro)-17β-estradiol in DMBA-induced mammary tumorsInternational Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology, 1987
- Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data. GeneralizationsJournal of Cerebral Blood Flow & Metabolism, 1985
- Dosimetry and preliminary human studies of 18F-5-fluorouracilInternational Journal of Nuclear Medicine and Biology, 1982
- Hypoxic Sensitizers — Implications for Radiation TherapyNew England Journal of Medicine, 1979
- Distribution of 18F-5-Fluorouracil in tumor-bearing mice and ratsInternational Journal of Nuclear Medicine and Biology, 1978